Mylan-Pfizer’s Upjohn deal will result in limited overlap, vertical integration, companies tell CADE
Global pharma company Mylan and Pfizer's off-patent drug business, Upjohn, have told the Brazilian competition authority that their deal will result in a limited overlap in the market for atypical antipsychotics,...To view the full article, register now.
Already a subscriber? Click here to view full article